Investor Presentaiton

PCV21 (SP0202) well-tolerated in pediatric population Safety profile comparable with PCV13 across all 4 doses. % of participants reporting Solicited injection site reactions 100 80 60 40 20 0 Dose 1 Dose 2 Dose 3 Dose 4 PCV21 PCV13 PCV21 selected formulation for next phase PCV21 Phase II [NCT04398706] 63 Vaccines Investor Event % of participants reporting Solicited systemic reactions 100 80 60 40 20 0 Dose 1 Dose 2 Dose 3 Dose 4 sanofi

View entire presentation